RecruitingPhase 2NCT03736863

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma


Sponsor

The First Affiliated Hospital of Zhengzhou University

Enrollment

147 participants

Start Date

Dec 5, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying different drug combinations for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) whose disease has continued growing or spread despite prior treatment. **You may be eligible if...** - You have been diagnosed with squamous cell carcinoma of the esophagus that is advanced, has spread, or cannot be surgically removed - You are aged 18–75 years - You have already received at least one round of chemotherapy or immunotherapy that did not work or was not tolerated - You have measurable cancer on imaging scans **You may NOT be eligible if...** - You have not yet received any prior treatment for your esophageal cancer - You have a different type of esophageal cancer (e.g., adenocarcinoma) - You have severe organ problems that would make treatment unsafe - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGApatinib+ SHR-1210(Camrelizumab)

Apatinib 250mg, q.d.po+SHR-1210(Camrelizumab)200 mg,Intravenous injection,q2W

DRUGApatinib+ SHR-1316(Adebrelimab)

Apatinib 250mg, q.d.po+SHR-1316(Adebrelimab) 1200 mg,Intravenous injection,q2W

DRUGSHR-1316(Adebrelimab)+SHR-A2009

SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,


Locations(1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03736863


Related Trials